- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01830335
Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress
The Influence of Cerebral Blood Flow and Alkalosis on Neuromuscular Function During Environmental Stress
Environmental stress, such as low oxygen availability (hypoxia), has been associated with impaired neuromuscular performance; however, the mechanisms associated with these performance decrements remain unclear. While the majority of research suggests that the observed fatigue is related to the central nervous system, the influence of changes in cerebral blood flow (CBF) and associated changes in cerebral pH (partial pressure of carbon dioxide; PCO2) remains unexamined. In response to hypoxic stress, humans hyperventilate to maintain oxygen consumption, resulting in a hypocapnia mediated decrease in CBF and cerebral alkalosis (decreased PCO2). Previous research suggests that hyperventilation induces changes in neural excitability and synaptic transmission; however, it remains unclear if these changes are related to hypocapnia mediated decrease in CBF or cerebral alkalosis or both.
The purpose of the proposed research program is to examine the influence of changes in CBF and cerebral alkalosis on neuromuscular function during environmental stress. The research program will consist of 2 separate projects, summarized below in a table outlining the proposed protocols and resultant physiological manipulations. During each manipulation, neuromuscular function will be evaluated and compared to baseline (normoxic) conditions using a repeated measures design.
The research program will consist of 2 separate projects. Project 1 will examine the changes in CBF and alkalosis by using (a) indomethacin (decrease CBF; no change PCO2) and (b) hypocapnia (decrease CBF; decrease PCO2). Using a similar experimental design, Project 2 will examine the change in CBF and alkalosis during hypoxia by using (a) poikilocapnic hypoxia (decrease PO2; decrease CBF; decrease PCO2), (b) isocapnic hypoxia (decrease PO2; no change CBF; no change PCO2) and (c) isocapnic hypoxia + indomethacin (decrease PO2; decrease CBF; no change PCO2). During each manipulation, neuromuscular function will be evaluated and compared to baseline (normoxic) conditions using a repeated measures design.
Therefore, Project 1 will examine the separate and combined effect of changes in CBF and cerebral alkalosis on neuromuscular function independent of environmental manipulations. Subsequently, Project 2 will examine neuromuscular function during hypoxia while controlling CBF and cerebral alkalosis. It is hypothesized that changes in PCO2 and therefore, changes in cerebral alkalosis will contribute to neuromuscular fatigue independent of changes in CBF and oxygen availability.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ontario
-
St Catharines, Ontario, Canadá, L2S 3A1
- Brock University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 18 to 25 yrs old; healthy males
Exclusion Criteria:
- diagnosed medical condition; NSAID allergy; smoker; high altitude exposure; implants
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Drug
Indomethacin 1.2 mg kg 1 dose
|
|
|
Comparador de placebos: Placebo
flour capsule
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Umbral motor en reposo
Periodo de tiempo: Cambio desde la línea de base 90 minutos
|
Los potenciales evocados motores se registran en los músculos después de la estimulación magnética transcraneal de la corteza motora.
El umbral motor en reposo se define como la intensidad de estimulación mínima necesaria para provocar un potencial evocado motor.
El umbral del motor en reposo se cuantificará en milivoltios.
|
Cambio desde la línea de base 90 minutos
|
|
Contracción Voluntaria Máxima
Periodo de tiempo: Cambio desde la línea de base 90 minutos
|
Durante la prueba de contracción voluntaria máxima (MVC), el brazo derecho de los participantes se asegurará en un dispositivo hecho a medida que se utiliza para aislar la flexión del antebrazo y medir la producción de fuerza del músculo flexor radial del carpo.
Se les pedirá a los participantes que produzcan un MVC de 5 segundos y se les alentará verbalmente a mantener la producción de fuerza máxima durante la duración de la contracción.
MVC se cuantificará como la máxima producción de fuerza en newton metros.
|
Cambio desde la línea de base 90 minutos
|
|
H-Reflex Amplitude
Periodo de tiempo: Change from baseline 90-minutes
|
The H-Reflex is an indirect measure of motor neuron excitability.
Initially, a maximal M-wave (M-max) will be elicited by stimulating (1 ms in duration; 15 s between stimuli) the median nerve incrementally (2 V increments) until the largest waveform is observed.
The peak-to-peak amplitude of this waveform is considered M-max.
Using similar procedures as above, a sub-maximal M-wave of 5% M-max will be elicited and the amplitude of the resultant H-reflex (a small waveform observed following the submaximal M-wave) will be calculated.
The amplitude of the H-reflex will be quantified in milllivolts.
|
Change from baseline 90-minutes
|
|
H-reflex latency
Periodo de tiempo: Change from baseline 90-minutes
|
The H-Reflex is an indirect measure of motor neuron excitability.
Initially, a maximal M-wave (M-max) will be elicited by stimulating (1 ms in duration; 15 s between stimuli) the median nerve incrementally (2 V increments) until the largest waveform is observed.
The peak-to-peak amplitude of this waveform is considered M-max.
Using similar procedures as above, a sub-maximal M-wave of 5% M-max will be elicited and the amplitude of the resultant H-reflex (a small waveform observed following the submaximal M-wave) will be calculated.
The onset latency of the H-reflex will be quantified in milliseconds.
|
Change from baseline 90-minutes
|
|
Voluntary Activation
Periodo de tiempo: Change from baseline 90-minutes
|
The level of neural drive to muscle during contraction is termed voluntary activation and will be estimated by interpolation of a single supramaximal motor evoked potential during the 5-second MVC contraction.
If extra force is evoked by the 'superimposed' stimulus then either the stimulated axons were not all recruited voluntarily or they were discharging at sub-tetanic rates.
Therefore, voluntary activation will be quantified as the amplitude of maximal voluntary force production, relative to the amplitude of the supramaximal MEP.
|
Change from baseline 90-minutes
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Velocidad del flujo sanguíneo de la arteria cerebral media
Periodo de tiempo: Cambio desde la línea de base 90 minutos
|
La velocidad del flujo sanguíneo de la arteria cerebral media (MCA) se medirá de forma no invasiva mediante una sonda de ultrasonido Doppler transcraneal (TCD) de 2 MHz, conectada bilateralmente a una diadema cómoda y asegurada anterior al arco cigomático, rostral del pabellón auricular.
Las sondas Doppler se colocarán sobre las ventanas temporales (cerca del oído) y permanecerán en su lugar durante la duración del protocolo experimental.
La velocidad de MCA se cuantificará en cm/s.
|
Cambio desde la línea de base 90 minutos
|
|
Brachial Artery Blood flow
Periodo de tiempo: Change from baseline 90-minutes
|
Brachial artery blood flow will be measured non-invasively using a high-resolution ultrasound machine.
Participants will lie supine with their forearm extended in a comfortable position.
Blood flow measurements will be taken in the top 1/3 of the upper arm over the duration of 10 cardiac cycles (approximately 60 seconds).
Blood flow will be quantified in L/min.
|
Change from baseline 90-minutes
|
|
Internal Carotid Artery Blood Flow
Periodo de tiempo: Change from baseline 90-minutes
|
Internal carotid artery (ICA) blood flow will be measured non-invasively using a high-resolution ultrasound machine.
Participants will lie supine with a slight extension of the neck and at 45° of lateral flexion away from the side being scanned.
ICA measurements will be taken 1 cm superior to the common carotid bifurcation over the duration of 10 cardiac cycles (approximately 60 seconds).
Blood flow will be quantified in L/min.
|
Change from baseline 90-minutes
|
|
Blood pressure
Periodo de tiempo: Change from baseline 90-minutes
|
Beat by beat blood pressure will be calculated from the blood pressure waveform using finger photoplethysmography (Nexfin, bmeye), with a finger cuff placed directly over the middle finger on the left hand.
Blood pressure will be quantified in mmHg.
|
Change from baseline 90-minutes
|
|
Pulse oximetry
Periodo de tiempo: Change from baseline 90-minutes
|
A pulse oximetry probe will be placed over a finger to provide a continuous, non-invasive measurement of the blood oxygen saturation to confirm that the end-tidal forcing system is controlling oxygen delivery at the desired levels during each experiment.
Oxygen saturation will be quantified as a percentage.
|
Change from baseline 90-minutes
|
|
Heart Rate
Periodo de tiempo: Change from baseline 90-minutes
|
Heart rate will be measured by electrocardiogram.
Heart rate will be quantified in beats per minute.
|
Change from baseline 90-minutes
|
|
End-Tidal Gas Concentrations
Periodo de tiempo: Change from baseline 90-minutes
|
The end-tidal concentrations of oxygen and carbon dioxide will be measured and reported in mmHg.
|
Change from baseline 90-minutes
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Stephen Cheung, PhD, Brock University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes del sistema nervioso periférico
- Inhibidores de enzimas
- Analgésicos
- Agentes del sistema sensorial
- Agentes antiinflamatorios no esteroideos
- Analgésicos no narcóticos
- Agentes antiinflamatorios
- Agentes antirreumáticos
- Inhibidores de la ciclooxigenasa
- Agentes de control reproductivo
- Supresores de gota
- Agentes tocolíticos
- Indometacina
Otros números de identificación del estudio
- 12-167
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .